The MacNew Instrument is protected by national and international laws. The Berne Convention and the national laws on intellectual property fully apply to the MacNew Instrument and its documents.
MacNew.org as the copyright holder of the MacNew Instrument controls access (distribution and reproduction), its adaptation or modification, and its translation. Copyright is a means to protect the integrity of an instrument.
Is there any paperwork/contract/other agreement that will be required for us to use it in our studies?
Yes, there is the requirement to agree in writing to our standard conditions for using the MacNew as outlined in the licensing contract.
Yes, after receiving written permission from us you may make copies of the pdf MacNew for your specific project. This will be granted after [you/company name] accepts the license agreement for the agreed on number of copies.
How do you finally score the questionnaire (especially if someone does not answer some of the questions)?
The MacNew scoring algorithm allows missing items as long as >50% of the items are scored.
Yes, we will provide the licensees with an Excel Scoring Sheet as well as an SPSS syntax file.
Are there separate versions of the MacNew for each of the three ischemic heart disease diagnoses, i.e., myocardial infarction, angina and heart failure? Is there a separate MacNew version for patients with a pacemaker?
The MacNew has been validated for patients with myocardial infarction, angina, heart failure and in patients with a pacemaker. In addition, normative data are available for patients with myocardial infarction, angina, and heart failure. The MacNew is the core patient reported outcome instrument assessing all three aspects of health (according to the health definition of the WHO: physical, mental and social well-being) in coronary artery disease patients.
Can the instrument be used effectively, from a few days after an acute MI to a few years after MI? Is there a time when this questionnaire is not as effective?
The MacNew questionnaire has a 2 weeks time frame and has been applied at different time points after the event/diagnosis as well as in the acute phase and is sensitive to change in HRQL with moderate to large effect sizes.
The MacNew has been validated in all major ischemic heart disease diagnoses (myocardial infarction, angina, heart failure) as well as in patients with a pacemaker with demonstrated effectiveness in these conditions.